KLRS

Kalaris Therapeutics
KLRS

Upgrade to unlock
Buy
Hold
Sell

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$19.5
99% upside
High target

2 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Chardan Capital
Chardan Capital
Daniil Gataulin
0% 1-yr KLRS win rate
23 Dec ‘25 28 days ago
Citizens
Citizens
Jonathan Wolleben
100% 1-yr KLRS win rate
3 Nov ‘25 2 months ago